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Genetic Discrimination:
Overview of the Issue and Proposed Legislation
Summary
A key policy issue before Congress is whether the potential for genetic
discrimination by employers and insurers merits protections for genetic information
that are more extensive than those already in place for health information.  For the
stated purpose of prohibiting discrimination on the basis of genetic information with
respect to health insurance and employment, the Genetic Information
Nondiscrimination Act of 2007 (H.R. 493) was introduced in the House on January
16, 2007.  On January 22, 2007, the act was introduced in the Senate (S. 358).  The
act is identical to the Genetic Information Nondiscrimination Act of 2005, which
passed the Senate by a vote of 98-0 (S. 306, 109th).  An identical House bill (H.R.
1227, 109th), never came to a vote.  S. 306 was very similar to S. 1053 (108th), which
the Senate passed in 2003 by a vote of 95-0.  A distinct House bill, H.R. 1910 (108th),
never came to a vote.  This report focuses on the key points in the ongoing debate
about genetic discrimination legislation.
S. 358 and H.R. 493 are supported by consumer groups, the medical profession,
researchers, the medical products industry (including pharmaceutical companies), and
President Bush, and are opposed primarily by the U.S. Chamber of Commerce.  Since
the first bills were introduced in the 103rd Congress, many of the arguments and
positions supporting and opposing genetic nondiscrimination legislation have
remained largely unchanged.  Supporters of nondiscrimination legislation feel that
current laws are not sufficient to protect individuals from discrimination in health
insurance or employment.  Supporters of the legislation further contend that without
protection, individuals are hesitant to seek potentially beneficial genetic services or
participate in much needed clinical research.  Opponents believe that current law
provides sufficient protection. They are primarily concerned that new legislation will
provide further incentives and  additional opportunities for litigation against
employers.  
  
Collectively, genetic diseases and common diseases with a genetic component
pose a significant public health burden.  With completion of the human genome
sequence, scientists are now focusing on the development of clinical applications
based on the sequence information.  One such application, clinical genetic testing, is
becoming available at a rapid rate, and some tests are beginning to be included in
health insurance benefits packages. Genetic testing may both facilitate and be
inhibited by the potential for genetic discrimination.  Issues surrounding
nondiscrimination addressed in this report include:
! What is health information and how is it currently used by health
insurers and employers?
! What is genetic information?
! Is genetic information different from other health information?  
! What evidence exists to suggest that discrimination is a problem?
! Would the proposed legislation be sufficient to protect “genetic
information” and “genetic tests” that are of concern?
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Genetic Discrimination:  Overview
of the Issue and Proposed Legislation
Introduction
In order for Congress to address the key issue that it faces with respect to genetic
discrimination, namely, whether the potential for genetic discrimination by employers
and insurers merits protections for genetic information that are more extensive than
those already in place for health information in general, there are several fundamental
points that it may wish to consider. These include an understanding of what genetic
information and discrimination are, how current laws affect employers’ and insurers’
use of genetic and other health information, how proposed legislation would amend
current law, and the arguments that have been made both in favor of and against the
passage of legislation. 
Properly defining genetic information in potential nondiscrimination legislation
is essential, as the scope of the definition will largely determine the types of activities
that are permitted and proscribed.  Yet this basic concept may prove to be complex,
as many types of health information have a genetic component. Genetic information
may be defined and derived in a number of ways.  Of course, it may be obtained via
genetic testing.  However, it may also be discernable through other laboratory testing
that does not involve a specific examination of genes, such as some protein or
molecular testing.  It may sometimes be derived through physical examination (for
example, Down’s syndrome, which has a genetic basis, has specific physical
characteristics such as a single crease across each palm).  Finally, genetic information
may be discernable from a family’s medical history, which might reveal risks for
certain types of cancer, hypertension, and a myriad of other diseases with a genetic
component.
Once the definition of genetic information is settled, the question of what
constitutes discrimination based on that information can be addressed.  In the context
of the current debate in Congress, genetic discrimination can be defined as the
potential use of an individual’s genetic information by employers or health insurers
to discriminate against that individual in employment decisions (hiring, promotions,
firing) or health insurance coverage decisions (eligibility or premiums).  Although the
use of health information, including genetic information, by employers and insurers
is currently regulated, some argue that genetic information merits special protections
under the law.
Three federal laws and a presidential order touch on the issues raised by the use
of genetic information:  the Americans with Disabilities Act (ADA); Title VII of the
Civil Rights Act of 1963; the Health Insurance Portability and Accountability Act
(HIPAA); and Executive Order 13145, To Prohibit Discrimination in Federal
CRS-2
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 For a more detailed discussion of legal issues relating to the use of genetic information, see
CRS Report RL30006, Genetic Information:  Legal Issues Relating to Discrimination and
Privacy, by Nancy Lee Jones and Amanda K. Sarata.
2
 The danger exists because certain genetic traits and predispositions can have higher
frequencies among individuals of certain ethnic backgrounds.  See Title VII of the Civil
Rights Act, as amended by Civil Rights Act of 1991, P.L 102-166, Section 105(a), codified
at 42 U.S.C. § 2000e-3(a);  and Norman-Bloodsaw v. Lawrence Berkeley Laboratory, 135
F.3d 1260 (9th Cir. 1998).
3
 State information on privacy at [http://www.ncsl.org/programs/health/genetics/prt.htm] and
employment at [http://www.ncsl.org/programs/health/genetics/ndiscrim.htm]. State
information on insurance is at [http://www.genome.gov/PolicyEthics/LegDatabase/pubMap
Search.cfm], and [http://www.ncsl.org/programs/health/genetics/ndishlth.htm]; accessed
Mar. 5, 2007.
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 M.A. Pagnattaro, “Genetic Discrimination and the Workplace: Employee’s Right to
Privacy vs Employer’s Need to Know,” American Business Law Journal, vol. 29 (2001), pp.
139-185.
Employment Based on Genetic Information (65 FR 6877).1  The ADA protects people
from discrimination based on existing disability, history of disability, and perception
of disability in employment.  The executive order prohibits discrimination against
federal employees based on protected genetic information, or information about a
request for or the receipt of genetic services. 
In general, the  HIPAA statute limits denial of coverage based on pre-existing
conditions to 12 months.  In the absence of a current diagnosis, the HIPAA statute
would not consider predictions of risk of future disease based on genetic information
to be a pre-existing condition.  In addition, the health information privacy rule, issued
in 2000 pursuant to HIPAA’s Administrative Simplification provisions,  restricts the
disclosure of health information, including genetic information, by group and
individual health plans.  The HIPAA privacy rule also allows group and individual
health plans to use some health information (which could include genetic information)
in underwriting.  The Civil Rights Act provides some protections against genetic
discrimination against members of a protected group, such as persons of a certain race,
color, religion, sex or national origin.2
The existence and scope of state anti-discrimination legislation that could be
interpreted to cover genetics varies.3  Most state laws prohibit:  (i) discrimination
based on particular traits or diseases; (ii) discrimination based on genetic test results;
or (iii) insurers or employers from requiring that an individual take a genetic test and
using the results.4
Legislation reintroduced in the 110th Congress (S. 358 / H.R. 493) has been
marked up by the House Committee on Education and Labor and the Senate
Committee on Health, Education, Labor and Pensions.  The legislation would extend
current federal protections against discrimination to health insurers in the individual
market, and would further limit the use and disclosure of genetic information.  The
CRS-3
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 See the next section of this report for more discussion of the scope and types of
information that could be used.
6
 U.S. Congress, Senate Committee on Health, Education, Labor, and Pensions, Genetic
Information Nondiscrimination Act of 2003, report to accompany S. 1053, 108th Cong., 1st
sess., S.Rept. 108-122, Genetic Information Nondiscrimination Act 2003 (Washington,
GPO, 2003), pp.12-15.  CRS Report RL30006, Genetic Information: Legal Issues Related
to Discrimination and Privacy, by Nancy Lee Jones and Alison M. Smith. 
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 Sheryl Gay Stolberg.  “President Calls for Genetic Privacy Bill,” at [http://www.nytimes.
com/2007/01/18/washington/18privacy.html?_r=1&ref=health&oref=slogin#]; accessed
January 18, 2007.
8
 The GINE Coalition is a business coalition of trade associations, professional
organizations, individual companies and their representatives.  In addition to the U.S.
Chamber of Commerce, the coalition includes the Society for Human Resource Management
(SHRM), the National Association of Manufacturers (NAM), the National Federation of
Independent Business (NFIB) and the College & University Professional Association for
Human Resources (CUPA-HR), among others.  The exclusive focus of the GINE Coalition
is the issue of genetic nondiscrimination in employment.
bills would also bar insurers from using genetic information or family history of
disease in underwriting for an individual (as an individual or applied to a group).5
S. 358 and H.R. 493 would also prohibit discrimination in employment because
of genetic information and, with certain exceptions, prohibit an employer from
requesting, requiring, or purchasing genetic information.  If such information were
obtained, the bills would require that it be treated as part of a confidential medical
record.  The bills include detailed provisions on enforcement which generally apply
the remedies available in existing civil rights laws such as Title VII of the Civil Rights
Act of 1964 (42 U.S.C. § 2000e-4 et seq).  Neither bill addresses life or disability
insurance.
Genetic nondiscrimination legislation has been debated since the 103rd Congress.6
Since that time, many of the arguments and positions supporting and opposing genetic
nondiscrimination legislation have remained largely unchanged.  On January 18, 2007,
President Bush called on Congress to pass bipartisan genetic nondiscrimination
legislation.7  Genetic nondiscrimination legislation is supported by consumer groups,
the medical profession, researchers and the medical products industry (including
pharmaceutical companies).   Opposition to genetic nondiscrimination legislation has
come from some members of the insurance industry and from employers, represented
broadly by the Genetic Information Nondiscrimination in Employment (GINE)
Coalition,8 which includes the  U.S. Chamber of Commerce.
Supporters of the legislation argue that current laws are not clear on protection
from discrimination based on genetic information; because existing federal laws have
not been tested in court, the extent of their protection of genetic information is not
assured.  Despite the fact that few cases of genetic discrimination can be documented,
supporters argue that proper protections are necessary to allay the fears of individuals
about the potential for discriminatory practices.  Allaying the public’s fears, they
argue, will encourage individuals to seek beneficial health services, participate in
CRS-4
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 Statement of Ronald Weich, on behalf of the American Civil Liberties Union, for inclusion
in the record of the hearing of the Senate Committee on Health, Education, Labor and
Pensions, July 25, 2001.
10
 Statement of the American Association of Health Plans Board of Directors, “Health Plan
Principles Guide Policies Toward Genetic Testing and Treatments,” Oct. 15, 2003, press
release.  The principles include the protection of all identifiable health information
(including genetic information) from illegal use, prohibition from discrimination in
insurance and employment based on health status, and use of genetic information to improve
the quality of patient care [http://www.ahip.org/content/pressrelease.aspx?docid=168],
accessed Mar. 5, 2007.
11
 National Association of Health Underwriters, Position on Genetic Testing, at
[http://www.nahu.org/legislative/Genetic_position.pdf]; accessed Mar. 3, 2007.
much-needed clinical research, and otherwise reap the benefits of the publicly funded
Human Genome Project (HGP). 
Many professional and consumer groups argue that individuals should not be
penalized in their ability to obtain insurance or a job because medical science can
identify a genetic condition or a gene that predisposes a person to a future illness, but
cannot yet offer an effective treatment.  For example, the American Civil Liberties
Union (ACLU) stated at a hearing in 2001 that “Americans should be judged on their
actual abilities, not their potential disabilities.”9   On the other hand, this may create
a disparity between people whose medical conditions have treatments available and
those whose do not.
Opponents of enacting special legislation to prevent potential discrimination on
the basis of genetic information argue that current federal and state protections are
sufficient. The insurance industry also argues that additional regulation would be
confusing, unnecessary and costly.  They claim that it would be unfair to prohibit them
from acquiring genetic information when they already use other health information.
Some groups, such as the American Association of Health Plans (now a part of the
America’s Health Insurance Plans), support the premise of federal nondiscrimination
legislation and have indicated support for legislation that is consistent with their
principles.10  However, others would further limit the definition of genetic
information.11  One bill introduced in the 108th Congress (H.R. 3636) would have
prohibited health insurers from discriminating based on predictive genetic information
but would not have affected employers.  The bill had no cosponsors, and many
consumer groups indicated that they would not support nondiscrimination legislation
without both insurance and employment provisions.
Some employers question whether legislation is necessary because there are few
documented cases of discrimination based on genetic information, and there is no
evidence that employers would use the information if they had it.  In addition,
employers argue that existing law provides adequate protection against genetic
discrimination in employment.  Randy Johnson, vice president of the U.S. Chamber
of Commerce’s office of labor policy, stated that if the legislation were to pass, it
should be narrowed to acknowledge that employers should be able to make
employment decisions based on information that some workers with specified genetic
CRS-5
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 David Hess, “Genetic Discrimination Bill Stalls in House,” Congress Daily, Apr. 20,
2004.
markers could pose a “significant risk to others.”12 Other business coalition members
suggest that the definition of “family member” should be revised to include only
immediate family.  Many also support federal preemption whereby any new federal
law would preempt existing state law in this area.
This report provides an overview of the scope and current permissible uses of
health information and genetic information.  It reviews the existing evidence of
genetic discrimination and the impact of the fear of discrimination.  Then it provides
a more detailed discussion of S. 358/H.R. 493 and the key issues raised by the genetic
nondiscrimination bills.  
For a more detailed discussion of genetic testing and public policy, see CRS
Report RL33832, Genetic Testing: Scientific Background for Policymakers, by
Amanda K. Sarata.
Health Information
Understanding how health information is currently used and regulated provides
a framework for discussion about whether extra protections are necessary for genetic
information, and if so, which protections are most appropriate.  Health information,
which includes genetic information, is currently used by health insurers and
employers.  It is often presumed confidential, but increasing capabilities to store and
rapidly transfer data electronically escalate the challenge of protecting privacy.   Both
the ways in which health insurers and employers use and are restricted from using
health information are discussed in the sections that follow.
Use of Genetic and Other Health Information 
by Health Insurers
Several federal laws help provide some protection against genetic discrimination
in health insurance.  These laws include the Health Insurance Portability and
Accountability Act (HIPAA) of 1996 (specifically Title I: Health Care Access,
Portability, and Renewability); the Social Security Act (SSA); and the HIPAA privacy
rule.  HIPAA prohibits group health plans from imposing a preexisting condition
exclusion on the basis of genetic information or establishing eligibility requirements
for any individual based on genetic information.  However, HIPAA does not prohibit
a group health plan from charging all members of a group higher premiums on the
basis of an individual’s genetic information.  The SSA contains provisions that
prohibit discrimination in the pricing or issuance of Medigap policies on the basis of
health status, but it does not specifically state that health status includes genetic
information.   
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The privacy rule gives patients the right of access to their medical information
and places certain limitations on when and how health plans and health care providers
may use and disclose medical information.  Generally, plans may use and disclose
information for their own treatment, payment, and health care operations without the
individual’s authorization and with few restrictions.  The rule covers all individually
identifiable health information, including genetic tests and information about an
individual’s family history.  The rule permits a group health plan to disclose
individually identifiable health information to an employer that sponsors the plan,
provided the information is used only for plan administration purposes.
Health insurers typically use family history, among many health factors, in the
process of placing individuals or groups in a risk category for determining their
premiums (underwriting).  Individuals or groups at higher risk may be charged higher
premiums to cover the anticipated costs of their care.  Traditional approaches to
underwriting also use age, sex, type of occupation, financial stability of group
members, employee turnover and prior cost (of care) experience to determine what a
group’s insurance premium should be.  
In general, premiums for a large group with one or two sick members can remain
relatively stable, as the cost of the sick individuals is spread among all members of the
group.  However, as groups become smaller, the cost of insurance for the group is
more dependent on the health of the individual group members, since one sick
individual in a small group can result in high premiums for the whole group.
Individuals who are not part of a group coverage, seeking to purchase individual
health insurance, must bear the entire premium increase associated with any illness,
thus making such insurance prohibitively expensive for many sick individuals.
Insurers claim that most genetic information is not currently useful to the
underwriting process because the clinical significance and relationship to the severity
of illness is not known for many conditions.  However, once the link to future illness
is established and the costs thereof become predictable, insurers’ use of genetic
information might be no different than the use of other diagnostic information.   Some
actuaries agree that adding diagnostic information significantly improves the power
of traditional underwriting methods to predict future medical expense.13 
One author has provided a model demonstrating how genetic information
(including family history) that has a known correlation to a specific disease, such as
Huntington’s disease or breast cancer, could be used to underwrite life insurance.14
Some health care providers and consumers fear that the model could also be applied
to health insurance.  The model’s author suggests that insurers support screening for
genetic mutations for which preventive interventions can reduce the risk of death.
However, health insurers may disagree, depending on the nature, expense and
effectiveness of the interventions in preventing symptoms and other medical costs of
treating an acute or chronic illness.  That which reduces the risk of death may not
CRS-7
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reduce health or disability expenses (and lower life insurance premiums).  In addition,
health insurers may be reluctant to bear the costs of preventive care.  Particularly in
a climate in which individuals change health insurers frequently, an insurer that pays
for prevention may not ultimately reap the financial benefits of avoiding the illness.
The problem of adverse selection. The predictive power of genetic testing
raises a concern for insurers about the possibility of adverse selection.  Adverse
selection can occur when an insurance applicant knows — and the insurance company
does not know — that the applicant has some health risk, possibly due to genetic
information.  In this case, the applicant may be motivated to purchase insurance with
greater coverage and may be able to do so at a lesser premium.   
Some argue that the specter of adverse selection requires that insurance
companies have access to genetic information, or else their financial solvency may be
threatened because individuals might obtain insurance at premiums that did not
accurately reflect their risk of expenditures.15  Others argue that concerns about
adverse selection with respect to genetic information may be unfounded.  The majority
of Americans receive their insurance through their employers, which are group rated
(i.e., premiums are based on an assessment of the average risk among all employees).
This system creates incentives for low-risk individuals to purchase coverage, thus
diminishing the potential impact of adverse selection.  In addition, some note that
genetic information about disease risk may prove to be so complicated as to be
essentially useless to an insurer.16  For example, for a complex multigenic disease,
there may be numerous genes involved, each of which contributes relatively little to
an individual’s risk of developing disease.  In addition, these variants will be modified
by environmental factors that further complicate the analysis.  
Use of Genetic and Other Health Information by Employers
One federal law, the Americans with Disabilities Act (ADA), may provide some
protections against employers’ use of employees’ genetic information.  The ADA
prohibits employers from revoking an offer, or from making other promotion
decisions on the basis of that health information.  Though genetics is not specifically
addressed by the ADA, the Equal Employment Opportunities Commission (EEOC)
interprets the ADA to mean that employees and/or job applicants cannot be required
to undergo genetic screening. However, current law permits employers to require
medical examinations of prospective employees who have been given conditional
offers of employment, if all employees in a similar situation are given the medical
exam.  Employers may also receive information related to applicants’ or employees’
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current disability or health status when the information is related to the individuals’
abilities to do their job.17
Supporters of genetic nondiscrimination legislation argue that because ADA does
not explicitly address genetics, the ADA protections that would be applied by the
court system are not clear.18  Opponents argue that the ADA protections are sufficient,
and that the proposed legislation is not clear on workplace situations where an
employee’s genetic makeup could interfere with the major functions of the
individual’s job or put others at risk of harm.
Another federal law, the Occupational Safety and Hazard Act (OSHA), may
permit employers to conduct some genetic tests on employees.  OSHA establishes a
legal duty for employers to protect employees from hazards in the workplace.
Although the statute does not require an employer to perform particular tests, the
employer may choose to implement programs that monitor employees’ potential
exposure to toxic or hazardous elements.  Standards for these programs allow for
genetic testing.19
Genetic monitoring for acquired damage resulting from exposure to a toxic
element is different from genetic screening for an inherited predisposition to an
occupationally related disease.20  For example, monitoring may be used to determine
if an employee is developing DNA damage from being exposed to asbestos.  On the
other hand, a different type of test could potentially determine if the employee were
more susceptible to asbestos damage to begin with.  The distinction may be relevant
should questions arise regarding whether any ill-health effects sustained by the worker
were a result of occupational exposure.
Genetic Information
As noted in the introduction, the definition of genetic information is a key issue
for Congress in its consideration of genetic nondiscrimination legislation, because the
broader the definition the more expansive the prohibitions on discrimination. The
definition of genetic information varies among sources.  Genetic information is
generally described as the information from a genetic test about genes, gene products,
inherited characteristics or other traits that are derived from an individual or an
individual’s family member(s).  Information about an individual’s current health status
(such as sex, age, results of physical examination, and chemical, blood, or urine
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analysis,  where the analyses do not provide information about an individual’s
genotype) is generally not considered to be genetic information.  The two key sources
of genetic information are family medical histories and genetic test results. 
Is Genetic Information Different 
from Other Health Information?
Understanding the ways in which genetic information is like and unlike other
types of information can help to inform the debate over the need for genetic-specific
nondiscrimination legislation.  Congress faces two questions on this topic.  First, is
genetic information different from other health information?  Second, if so, do the
differences indicate that genetic information merits additional protections?
Genetic information has been described as being different from other health
information because of factors such as its stability, its unique predictive qualities, its
potential use for individual and familial identification, and the impact that public fear
of discrimination is having on the behavior of patients and healthcare providers.
Some argue that these factors may make the misuse of genetic information particularly
detrimental to individuals, and, therefore, that the information deserves special
protections.  Further, they argue that the public health benefits that could come from
large-scale genetic research and the utilization of new genetic technologies may not
be fully realized unless public fear is assuaged by genetic nondiscrimination
legislation.  
Those opposed to special protections assert that genetic information is
fundamentally no different than other health data, at least not in ways relevant to
special protections, and that genetic information is already adequately protected by
medical privacy laws.   The Senate report for S. 1053 (S.Rept. 108-122), the genetic
nondiscrimination bill that was passed by the Senate in 2003, included the statement
that eventually “it may not be possible or even desirable in health care delivery or
scientific research to isolate genetic information as it pervades health information.”
To address the question of whether genetic information merits special
protections, one study compared the experiences, attitudes and beliefs of persons with
genetic conditions (cystic fibrosis and sickle cell disease) to those with other serious
medical conditions (diabetes, HIV, breast cancer and colon cancer) and to persons at
risk for developing a disease (breast or colon cancer) due to strong family history. The
authors found that in most instances, patients felt strongly that their health information
needed to be protected regardless of whether it was genetic.  In fact, respondents
indicated that information about non-genetic stigmatizing conditions —  such as
abortion history, mental health history, drug and alcohol history, HIV status, and
sexually transmitted disease — needed special protection.  Based on their findings, the
authors concluded that separate privacy policies for genetic and non-genetic health
information would be unwarranted.21
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Other studies and public opinion polls suggest that patients and members of the
community desire and may benefit from additional protections for their genetic
information.22  A 2003 study of 470 people with a family history of colorectal cancer
showed that nearly half rated their level of concern about genetic discrimination as
high. Those individuals with high levels of concern indicated that they would be
significantly less likely to consider meeting with a health care professional to discuss
genetic testing, or to undergo testing.  A 2004 survey by the Center for Genetics and
Public Policy found that 92% of survey respondents thought employers should not
have access to their genetic test results, and 80% opposed letting insurance companies
have access to results.
What Evidence Is There 
That Genetic Discrimination Exists?
Critics of genetic nondiscrimination legislation have argued that legislation is not
necessary because genetic discrimination is not occurring.  There have indeed been
relatively few reported cases of genetic discrimination in health insurance and
employment.  Rothenberg and Terry hypothesize that this is because:  (1) the use of
genetic information by employers and insurers is not widespread; (2) affected persons
may not know the underlying basis for adverse employment or insurance decisions;
and (3) many cases may go unreported because of disincentives associated with
publicizing discrimination lawsuits.23  Reports of cases of genetic discrimination and
genetic testing by employers are presented below.
Cases of Genetic Discrimination  
There have been a few studies of the prevalence of genetic discrimination in
health insurance, employment, and other settings, and these studies are quite dated.
One study reported that 22% of survey respondents indicated that they or a family
member were refused health insurance as a result of a genetic condition.24  This study
was strongly criticized by the Health Insurance Association of America (HIAA) at the
time, which argued that there is no evidence showing that insurers engage in genetic
discrimination, and that federal legislation to prohibit discrimination based on genetic
information is unnecessary.25  However, another study found that a number of
institutions, including health and life insurance companies, health care providers,
blood banks, adoption agencies, the military and schools, were reported to have
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engaged in genetic discrimination against asymptomatic individuals.  The alleged
discriminatory practices included an insurance company treating a genetic diagnosis
as a preexisting condition, an adoption agency refusing  to allow a woman at risk for
Huntington’s disease to adopt a child, and an employer terminating an employee after
the employee disclosed a risk of Huntington’s disease.26
On October 18, 2004, several individuals shared stories of genetic discrimination
with the Secretary’s Advisory Committee on Genetics, Health and Society
(SACGHS).27  These cases are highlighted below:
! Phil Hardt has hemophilia B, a bleeding disorder, and Huntington’s
disease. He testified that a human resource manager for an early
employer had indicated that he should withhold information about his
hemophilia and any bleeding episodes from his employer or he would
never be promoted or trained.  In addition, he indicated that his
daughter was unable to receive mortgage life insurance unless she
tested negative for Huntington’s disease. His grandson was denied
health insurance because of the hemophilia B that he inherited, and
he was forced to accept lower wages so that they could qualify for
state welfare and insurance coverage.  Two of his other children
decided to pay out of pocket to be tested anonymously for
Huntington’s disease to protect them from discrimination.  Mr. Hardt
applied — and was rejected — for long-term care insurance.
! Rebecca Fisher, a mother and early-onset breast cancer survivor with
a strong family history recounted how her employer, a small, self-
insured community hospital, was more concerned that the cost of her
bone marrow transplantation and other health care had exceeded the
cap for that year than with her health or productivity.   
! Tonia Phillips, a woman with a BRCA1 mutation in her family, chose
to undergo prophylactic surgery to reduce her risk of breast and/or
ovarian cancer.  After her procedures, her employer-sponsored health
insurance policy had increased by $13,000.  Her employer asked her
to switch to her husband’s policy, and in doing so, indicated that she
would receive a wage increase.
! Paula Funk, another individual who carried a BRCA1 mutation,
indicated that, because of the potential for discrimination, she and her
family paid out of pocket for testing so her physicians and health care
providers would not write her BRCA1 status on insurance claims
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forms.  She further testified regarding her difficulty in finding an
insurance company that would cover herself and her husband, co-
owners of a small business, as a group so that their premiums would
be affordable, given her family history and genetic testing status.
! Heidi Williams, an individual diagnosed with alpha-1 antitrypsin
deficiency,28 also spoke at a press conference at the House of
Representatives on April 1, 2004.  She explained that a large health
insurance company (Humana) had denied health insurance coverage
for her two children on the basis that they were carriers of alpha-1
antitrypsin disease.  Carriers only have one copy of an abnormal gene,
and typically do not exhibit symptoms of the disease.  After receiving
inquiries from the Genetic Alliance (a consumer advocacy
organization) and the press, the insurance company reversed its
decision to deny coverage, and provided six months of free coverage.
! On July 20, 2000, Terri Seargent, also an individual diagnosed with
alpha-1 antitrypsin deficiency, filed a statement with the Senate
Health, Education, Labor and Pension Committee indicating that soon
after her diagnosis, she was unexpectedly released from employment.
Without a job, and having a pre-existing condition, she also lost her
health, life and disability insurance. Later, an investigation by the
Equal Employment Opportunity Commission (EEOC) supported her
allegation of discrimination under the Americans with Disabilities
Act (ADA).29
It is difficult to gauge the appropriate weight that clusters of stories like those
above should have in the policy arena.  On one hand, drawing broad conclusions based
on a few examples may not be valid.  On the other hand, obtaining information from
a representative sample of the population may be difficult, because individuals  may
be reluctant to share their personal genetic information. 
Genetic Testing by Employers  
Employers’ testing of employees for genetic markers is not currently believed to
be a widespread practice; however, surveys of employer practice and employee
experience indicate that some instances exist.  No cases of employment discrimination
based on genetics have been decided in a federal court or the U.S. Supreme Court.
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However, several have been brought or threatened, and two cases were settled out of
court.30
Surveys of Employers. Employers have long been interested in identifying
“optimal” employees using non-health characteristics — such as behavior (i.e.,
substance abuse, mental instability, compulsive disorders) or intelligence — to
identify special skills or deficits that are predictive of productivity.31  Though
behavioral genetic testing is not ready for commercial use (largely due to the very
complex interaction of genes and the environment), other forms of testing are
common. 
The American Management Association (AMA) has conducted several surveys
of employers’ medical testing practices.  In a1998 survey,32 the AMA questioned the
employers about their use and understanding of what constituted a genetic test.
Respondents were presented with National Institutes of Health’s definition of genetic
test: “an analysis of human DNA, RNA, chromosomes, proteins, and certain
metabolites in order to detect heritable disease-related genotypes, mutations,
phenotypes, or karyotypes for clinical purposes.  Such purposes include predicting risk
of disease, identifying carriers, and establishing prenatal and clinical diagnosis or
prognosis.”  Only two respondents (out of 1,627) indicated that they performed
genetic testing.  A larger percentage (14.3%) indicated testing for “susceptibility to
workplace hazards.”  The results were modified by a 1999 follow-up survey in which
AMA found that not all of the testing their 1998 respondents had characterized as
“genetic” actually was.33  Only nine of 44 employers who indicated having testing
programs actually had genetic testing programs.  Some employers believed that any
blood test constituted genetic testing; others believed that diagnostic testing, rather
than susceptibility testing, was genetic testing.  
In 2001, the AMA conducted another survey of employers’ medical testing
practices.34  The results indicated that 68% of major U.S. firms required medical
examinations for new hires, current employees, or both.  These were most frequently
required in public administration and manufacturing positions and less frequently in
business or professional positions.  Establishing “fitness for duty” was the leading
reason that firms engaged in complete medical examinations (48% of respondents).
Testing for illegal substance use was the most common form of workplace testing,
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practiced by 67% of employers.  Some employers also reported testing new or current
employees for the genetic diseases sickle cell anemia (1.3%) or Huntington’s disease
(0.4%), and a larger proportion asked about family medical history (20.1%).  In
addition, some employers indicated that they used the medical test results — about
sickle cell anemia (1.0%), about  Huntington’s disease (0.8%), and about family
history (5.5%) — for purposes of hiring, reassigning, retaining or dismissing
employees. 
Surveys of Consumers. A 1996 study of 332 consumers who were members
of genetic support groups found that 13% of respondents reported that they or another
family member were denied a job or let go because of a genetic condition in the
family.35  The experience was significantly different for  respondents who had a
genetic condition (21%) compared to respondents who did not have a genetic
condition (4%).  Two examples were highlighted:  one respondent, a man with a sex
chromosome disorder, indicated that he was denied a job when a doctor wrote the
name of the disorder on his medical report during his pre-employment physical.  The
potential employer told the applicant of the decision and, knowing it was illegal, also
stated that they would deny having the conversation.  In the second example, a woman
with a skeletal disorder reported that her employment was terminated after she
informed her employer of her diagnosis.  The woman sought legal counsel, and the
termination was withdrawn.
Authors of a recently  published study interviewed approximately 100 adults or
parents of children with sickle cell disease, cystic fibrosis, diabetes, and HIV, and 200
adults with or at risk for breast or colon cancer about their experiences and attitudes
regarding health insurance.36  Twenty-seven percent of the respondents self-reported
having been denied health insurance or offered insurance at a prohibitively expensive
rate. Respondents with sickle cell disease and cystic fibrosis were twice as likely to
report this as those with non-genetic conditions (e.g., HIV).  More than one-third of
all respondents thought there was a high chance they would be denied health insurance
in the future or their insurance would become unaffordable.  While the study may
have suggested that insurers make decisions based on genetic information or diseases,
S. 358 / H.R. 493 would only limit discrimination due to genetic predisposition to
diseases.  The bills would have no effect on insurance availability or costs for people
like many of those in the study who had manifested genetic diseases.  
Court Cases and Legal Settlements.  To date, there have been two court
cases alleging genetic discrimination.  In 2002, Burlington Northern Santa Fe Railway
Corporation, one of the country’s biggest railroads, agreed to pay $2.2 million to settle
charges related to genetic testing and discrimination.  Employees charged those who
had filed for workers compensation for carpel tunnel syndrome (CTS) were tested
without their knowledge for a genetic marker dubiously associated with the syndrome.
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CTS is a painful hand and wrist condition caused by repetitive motion.  The railway
denied violating the law, and insisted that testing was necessary to determine the cause
of injury to 36 employees who claimed to have job-related CTS (20 actually
underwent testing before the program was voluntarily suspended).  Burlington
Northern halted the testing under the terms of a settlement shortly after a lawsuit was
filed.37
In another case, Lawrence Berkeley Laboratory was accused of conducting
pre-employment screening for sensitive medical information, testing for genetic traits
such as sickle cell trait, and for non-genetic factors such as syphilis and pregnancy.38
The case was settled out of court in 1999.  Prior to settlement, the employees had filed
a court case, claiming that the Laboratory had violated Title VII and right to privacy
as guaranteed in the U.S. and California Constitutions.  In response, the laboratory
sought to have the case dismissed without a trial (in summary judgement), claiming
that the employees had waited so long after the alleged testing to file their case that
their right to sue had expired (the statue of limitations had tolled).   On this issue, an
appellate court sided with the plaintiffs, determining that the question of when
employees knew or had reason to know that the laboratory was conducting testing
should be decided by a court (issues of material fact existed), thus precluding
summary judgement.  (Norman-Bloodsaw v. Lawrence Berkeley Laboratory (135 F.3d
1260, 1269; 9th Cir. 1998)).
Impact of the Fear of Discrimination on Behavior
 
While there are few documented cases of genetic discrimination by employers
and health insurers, studies have shown that public fear of discrimination influences
both the use of genetic testing and the use of genetic information by consumers and
health professionals.  Fear of genetic discrimination may cause consumers to refuse
genetic testing and therapies that could be beneficial to their health. It may deter
people from participating in genetic research, thus slowing the development of new
technologies.  In other words, whether or not genetic discrimination is actually
occurring, public worry about the issue may itself have detrimental effects.  Related
questions have been raised about whether genetic counseling, in which professionals
inform and assist patients making genetic-related healthcare decisions, may serve to
unduly increase the fear of discrimination, amplifying the behavioral impact.  Both
examples of the behavioral impact of genetic discrimination and investigation into the
role of genetic counseling are presented in this section.
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Examples of the Impact of Fear of Discrimination on Behavior
In January 2000, the Secretary’s Advisory Committee on Genetic Testing
(SACGT) sponsored a public forum that focused on the impact that the fear of genetic
discrimination was having on various groups.  SACGT received comments from
patients, consumers, health professionals, scientists, genetic test developers, educators,
industry representatives, policymakers, lawyers, students and others representing a
wide range of diverse ethnic and racial groups, and from a survey mailed to 2,500
individuals.39  The comments revealed  several anecdotal cases of discrimination, and
resulted in the committee forwarding two letters to the Secretary of Health and Human
Services (HHS) urging support for nondiscrimination protections:
During consultations with the public SACGT heard from many Americans who
are concerned about the misuse of genetic information by third parties, such as
health insurers and employers, and the potential for discrimination based on that
information.  Many stated that fear of genetic discrimination would dissuade them
from undergoing a genetic test or participating in genetic research studies. Others
stated that they would pay out of pocket for a genetic test to prevent the results
from being placed in their medical record.  Such concerns are a deterrent to
advances in the field of genetic testing and may limit the realization of the
benefits of genetic testing.40
Some examples of the specific impact that the fear of genetic discrimination has
on behavior were provided in October 2004, when several individuals testified at a
SACGHS meeting:41
! Carolina Hinestrosa, a 10-year, two-time survivor of breast cancer
and executive vice president for programs and planning of the
National Breast Cancer Coalition stated that despite her strong
personal and family history, she has not undergone genetic testing for
fear of discrimination against herself and her daughter.
! A mother, Phaedra Malatek, described how her family has not taken
advantage of the health benefits of genetic testing for
hemochromatosis that ran in her family because of their fear of losing
their health insurance, and possible discrimination against her
children when they seek employment.
Surveys of professionals and patients suggest that individuals are most likely to
withhold information about genetic testing from insurance companies and their
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employers.  A survey of genetic counselors42 found that, should counselors themselves
be at risk of developing  either breast cancer or hereditary non-polyposis colon cancer,
most (108 out of 159 surveyed) would not submit charges to their insurance
companies primarily because of the fear of discrimination.  Twenty-five percent would
use an alias when obtaining a test to reduce the risk of discrimination and maximize
confidentiality.  Most respondents indicated that, while they would share results with
their physicians, family and friends, 60% would not share the information with
colleagues because of the need for privacy and fear of job discrimination based on the
result.43
Of 91 participants in a study on hereditary pancreatitis, 22% believed that
knowing their test results “might lead to medical insurance discrimination” for
themselves or their families.  While most individuals would share information with
a physician or their family, only 4% indicated they would share results with their
insurance companies, and 20% would share them with their employers.44  Another
study of 98 extended families with a history of breast or ovarian cancer, reported on
716 of 1,315 individuals who underwent counseling and DNA testing.  Before
receiving results, about half were concerned about insurance discrimination, and 1%
indicated that they felt strongly that their family history of cancer had been the basis
for insurance discrimination.45
A group of scientists at the University of Michigan offered genetic testing for
susceptibility to breast cancer to 184 individuals participating in a cancer risk
evaluation clinic.  Patients were charged about $225 for the initial consultation, and
were required to pay Myriad Genetics directly for any testing they pursued.  At the
time, Myriad charged $395 for analysis of a single mutation, $450 for analysis of three
common mutations found in individuals of Ashkenazi Jewish descent, and $2,400 for
full sequencing of the breast cancer susceptibility genes (also called BRCA1 and 2).
Patients had the option of self-paying, or billing their insurance companies.  Though
discussion of potential discrimination was standard practice in the counseling session
that accompanied testing, the researchers only counted concerns initiated by the
patient during the session.  Of the 184 patients, 106 underwent testing.  Of the 78
patients who declined testing, 48 (or 26% of the original cohort of 184) declined due
to concerns about cost, confidentiality or insurance discrimination.46  The authors
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found it difficult to separate these concerns.  Although a patient may have wanted to
self-pay for fear of potential discrimination, the high cost of testing may have forced
the patient to choose to bill insurance, or decline testing.  The authors estimated that
approximately 14% of patients eligible for testing would have had a BRCA mutation,
but would not undergo testing because of cost, discrimination, or confidentiality
concerns. 
A follow-up telephone interview was conducted with 92 of the 184 patients
concerning their actual experiences with their insurance companies.  Of the 92, 15%
paid out of pocket, intentionally not involving their insurance companies, while 38%
(35 of 92) indicated that they did not have any problems obtaining insurance coverage
for the services requested.  However, of those 35 patients, 23 only requested payment
for the consult and surgery — not the testing — from their insurers.  The remaining
47% experienced various difficulties in obtaining coverage for some or all of the
services.  The patient’s family income was a significant factor in the decision to seek
insurance reimbursement.  In another study of 68 patients offered genetic testing for
breast cancer, while 18 had access to free testing, and 13 sought insurance
reimbursement, the remaining 37 chose to pay out of pocket citing concerns over
insurability and confidentiality reasons.47  Other authors have postulated that those
with the lowest income who were covered by government healthcare programs, such
as Medicaid, may be less concerned about genetic discrimination because their
eligibility for health insurance does not depend on health status or underwriting
decisions.48
The Role of Genetic Counseling 
When viewing evidence of the ways in which fear of genetic discrimination
affects behavior, some have questioned whether genetic counseling itself may
inadvertently add to the fear.  The risk of discrimination by employers and insurers is
often discussed in the counseling session that accompanies testing.  Most counselors
typically spend up to 15 minutes of a one- to two-hour counseling session discussing
patient concerns about discrimination, even in states with more comprehensive anti-
discrimination laws.  Counselors typically note that actual cases of discrimination are
few, and will provide information regarding the various legal protections.49  While
many counselors indicate that a significant proportion (25-50%) of patients may
decline testing due to potential discrimination, other patients accept testing because
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the benefits of the information to their health or the health of a relative outweigh the
risk of discrimination.  Either way, counselors note that the potential risk adds to an
already stressful situation.
In order to reassure patients about privacy, genetic counselors may vary their
practices in several ways:  they may be discreet about how a visit is documented (i.e.,
for cancer screening, not genetic testing); they may not send the results to the referring
physician unless asked specifically by the patient to do so; or, they may request that
the physician keep the results in a separate medical record.  Some will forward coded
samples to the laboratories for testing.  Many genetic counselors will themselves
maintain patient files that are separate from the rest of the hospital or medical center’s
records to minimize the possibility that an insurer will obtain genetic information in
the process of reviewing a medical record for reimbursement.50
Genetic counselors note that the fears associated with predictive testing for future
adult onset illness are not as apparent in testing in the prenatal and pediatric
populations.  Presumably this is because of the “crisis atmosphere” created with the
diagnosis of a potential birth defect and the parents’ decision of whether or not to
terminate a pregnancy.  In some cases including those involving newborns, the fear
of insurability may be mitigated by the fact that children are covered under their
parents’ policies.  However, some counselors have expressed concern about the way
in which genetic information will be viewed when children become adults and have
to find insurance on their own.51
The Genetic Information Nondiscrimination Act 
of 2007 (S. 358/H.R. 493)
The Genetic Information Nondiscrimination Act of 2007 would restrict insurers’
and employers’ acquisition and use of genetic information in several ways.  These
restrictions build upon those already imposed in current law.  The specifics of the
proposed restrictions have sparked debates in both the employment and insurance
arenas since they were first proposed.  This section of the report summarizes the
current privacy protections in place for both insurers and employers, and then surveys
the persistent debates that have accompanied genetic nondiscrimination legislation
generally.
Title I:  Genetic Nondiscrimination and Health Insurance
Title 1 of S. 358 and H.R. 493 would extend the current HIPAA protections
against discrimination by group health plans and issuers of health insurance in both
the group and individual markets, and restrict their acquisition, use and disclosure of
genetic information.  Currently, group plans and insurance issuers may require
individuals to provide genetic information or undergo genetic tests as a condition of
issuing coverage.  The HIPAA privacy rule permits plans and insurers to use and
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disclose genetic information for health care operations, a broadly defined term that
includes underwriting, premium rating, and other activities related to the creation,
renewal, or replacement of an insurance contract.
Under HIPAA’s current group market protections against discrimination, plans
or insurance issuers may not: (1) deny enrollment to an individual enrolling as part of
a group based on the individual’s health status, which is defined to include genetic
information; or (2) charge individuals enrolling as part of a group more than others in
the group based on genetic information.  However, insurers may charge the entire
group more based on genetic information about an individual or individuals within the
group.  In the individual market, HIPAA permits insurers to set premiums based on
an applicant’s genetic information, or deny that applicant coverage if the individual
is not HIPAA-protected (although some states prohibit such activity).52
The bills would place the following restrictions on group health plans and health
insurers.
Genetic Testing Requirements Prohibited.  The bills would prohibit
group plans and insurers from requesting or requiring that individuals or their family
members undergo a genetic test.  However, they would not limit the ability of a health
care professional to provide health services even if they were employed by or
affiliated with a group health plan or health insurance issuer.  That is, health care
professionals who are providing care may request or suggest that individuals or their
family undergo a test.
Use and Disclosure of Genetic Information Restricted.  The bills would
prohibit group plans and insurers from requesting, requiring, purchasing, using or
disclosing genetic information for the purposes of underwriting, eligibility
determination (before or during the enrollment process), premium rating, or the
creation, renewal, or replacement of a health insurance plan or contract.  “Incidental
collection” of genetic information would not be considered a violation.
Health Insurance Discrimination Disallowed.  The bills would  prohibit
plans and insurers in the group health insurance market from: (1) denying enrollment
to an individual based on genetic information about that individual or their family
members (as noted above, a similar nondiscrimination provision is already in
HIPAA); and (2) adjusting a group’s premium based on genetic information about an
individual in the group or their family members.  In the individual market, the bills
would prohibit insurers from denying enrollment or adjusting premiums based on
genetic information about the individual or their family members.
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Penalties for Violations Permitted.  The bills would permit the Secretary
to impose a penalty of $100 per day during a period of noncompliance with the
provisions in Title I.  Where willful neglect was found, they would establish a
minimum penalty of $2,500, or $15,000 for more severe or prolonged violations.
Title II:  Genetic Nondiscrimination and Employment
Title II of S. 358 and H.R. 493 would make it unlawful employment practice for
an employer to discriminate against an employee on the basis of genetic information.
Employers also would be prohibited from acquiring genetic information, except under
certain specified circumstances (see below).  The bills would cover employers and
employees as defined in Sections 701 and 717 of the Civil Rights Act of 1964, state
employees and employers described in the Government Employee Rights Act of 1991,
employees and employers described in the Congressional Accountability Act of 1995
and as defined in Section 3 U.S.C. 411(c), and job applicants.  The bills would place
the following restrictions on employers.
Genetic Testing Requirements Prohibited.  The bills would prohibit
employers, employment agencies and labor organizations from requiring or requesting
that an individual or a family member undergo a genetic test.  However, they would
not limit the ability of a health care professional to provide health services; that is,
health care professionals who are providing care could request or suggest that
individuals or their family members undergo testing in the context of providing care.
Discrimination in Employment Practices Disallowed.  The bills would
prohibit employers, employment agencies, and labor organizations from using genetic
information when making decisions about employees’ or applicants’ hiring,
promotion, or eligibility or selection for training programs or apprenticeships.
Acquisition of Genetic Information Restricted.  Generally, the bills
would prohibit employers, employment agencies, and labor organizations from
requesting, requiring or purchasing genetic information.  They would allow
employers, employment agencies and labor organizations to acquire genetic
information about an individual in the following circumstances:
! when they offered a health service program;
! when the employee provided written authorization;
! when the information was used to monitor the biological effects of
toxic substances in the workplace, but only if: 
 — the genetic monitoring was required by federal or state law;
 — the employee provided written authorization;
 — the employer provided written notice of genetic monitoring;
 — the employee was informed of the monitoring results;
 — the monitoring was conducted in compliance with federal genetic
monitoring regulations; and
 — the identity of specific employees was not disclosed.
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 45 C.F.R. Part 46 contains the Department of Health and Human Service’s regulations
governing the protection of human subjects in research.  Subpart A of these regulations is
known as the “Common Rule” because 17 other federal agencies have adopted parallel
requirements. 
In addition, the proposed bills would allow an employer to obtain genetic
information in the following situations:
! when the employer inadvertently requested or required family
medical history;
! when the employer offered health or genetic services, and the
individual provided authorization;
! when the identity of specific employees was not disclosed;
! when the employer requested information to comply with Section 103
of the Family and Medical Leave Act; and
! when the employer purchased publically available documents that
may have included family medical histories (books, magazines, etc).
Management of Genetic Information Specified.  The bills would treat
genetic information as part of the individual’s confidential medical record, and require
the employer to maintain separate forms or files for genetic information if they
obtained it.  Disclosure of information would be prohibited except when disclosure
is:
! to the individual or employee at their request (including family
members if family members are receiving services);
! to an occupational or other health researcher in compliance with 45
CFR Part 46;53
! in response to a court order when the employer has given the
employee notice and sufficient time to challenge the order; and
! to government officials investigating compliance with Title II.
Limitations on disclosure would apply to the employer, employment agency,
labor organization and labor-management committee.  With regard to disclosure under
a court order, the bills would  limit disclosure to only the genetic information
specifically authorized in the order, and would include an exception on disclosure
made in connection to an employee’s compliance with certification provisions of
Section 103 of the Family and Medical Leave Act.
Study of Violations Required.  S. 306 and H.R. 493 would not limit
employees’ rights or protections under the ADA or Rehabilitation Act of 1973 or any
other federal or state statutes.  The bills would establish a commission to review the
science of genetics and make recommendations on whether the “disparate impact” is
necessary to continue to protect individuals from situations where an employer (with
no discriminatory intent) unwittingly violated the law, and as a result, disproportionate
adverse effects are experienced by some individuals with certain genetic information.
  The bills would not apply to the Armed Forces Repository of Specimen Samples for
the Identification of Remains.  
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 45 C.F.R. 164.504(f).  The rule permits the following types of disclosure of health
information to a plan sponsor without amending the plan documents: (1) disclosure of
summary information (identifiers removed), if requested, for the purpose of obtaining
premium bids or modifying, amending or terminating the group plan; and (2) disclosure of
information on whether an individual is enrolled in or has disenrolled from a plan.
Selected Legislative Issues
Debate about genetic nondiscrimination legislation has continued since such bills
were first introduced in the 103rd Congress.  In order to fully appreciate the debate,
an understanding of how the HIPAA privacy rule currently governs insurers’ and
employers’ use of health information is useful.  The sections that follow present
background about the privacy rule, and then present several of the issues that have
been the topic of debate over time.      
Privacy Rule Background. In general, the privacy rule covers all individually
identifiable health information that is created or received by a health plan or health
care provider, including genetic information and information about an individual’s
family medical history.54  Plans and providers may use and disclose health information
for their own treatment, payment, and other routine health care operations without
patient authorization and with few restrictions.  The rule, however, does not apply to
other entities that collect and maintain health information such as financial institutions
that offer life insurance.  Employers that sponsor health plans on behalf of their
employees present a challenge for the rule’s implementation because of their
interrelationship with the insurer or health maintenance organization (HMO) that
typically administers the plan.  In their role as plan sponsor, employers may seek
health information to carry out various plan functions. 
While the rule in general does not regulate employers, it does address the use and
disclosure of health information (including genetic information) by employers that
sponsor group health plans.  The rule permits a group health plan, a health insurance
issuer, or an HMO acting for a group health plan to disclose health information to a
plan sponsor (employer), provided the plan documents are amended so that they limit
the uses and disclosures of information by the sponsor to those consistent with the
privacy rule.  In addition, an employer must certify to a group health plan that it will
not use the information for employment-related actions (e.g., hiring and promotion
decisions).  The employer must agree to establish adequate firewalls, so that only
those employees that need health information to perform functions on behalf of the
group health plan have access to such information.55
Title I:  Is the Privacy Rule Sufficient to Protect Consumers?  S. 358
and H.R. 493 would extend privacy rule protections to insurance and employment
functions to clarify the permitted uses of information as exchanged between plan
sponsors (employers) and group health plans.  Some have questioned whether these
additional privacy and confidentiality provisions are necessary.  Others have argued
that while HIPAA addresses what to do with information that has already been
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obtained, the proposed bills would address more specifically the acquisition of
information. 
Titles I and II: Would Legislation Actually Increase Utilization?  Title
II of S. 358 and H.R. 493 would require employers to keep genetic information in files
separate from other employee medical information.  This requirement would not apply
to groups covered by Title I (health insurers), even those that are sponsored by
employers as employee benefit packages, and would not affect the use of services
within the group health plan.   In previous Congresses, some expressed concern that
the legislation, which was intended to increase utilization of health care services and
participation in clinical studies, would actually reduce utilization because the overly
burdensome separate file requirement would raise the cost of providing genetic
services and would affect insurers’ willingness to pay for them.  Others argued that
the separate file requirement was not particularly burdensome (the privacy rule already
requires employers limit access to employees’ protected health information).  They
further argued that the separate file requirement was restricted to employers and would
not affect insurers or their customers.
Title I:  Would the Minimum Penalty Encourage Frivolous Lawsuits?
The bills provide that, when Title I is violated and willful neglect is found, there is a
minimum penalty of $2,500.  For more severe or prolonged violations, the minimum
penalty is $15,000. Some have argued that the establishment of a minimum penalty
would increase the incentive for individuals to sue health plans for violations of
privacy or denial of coverage based on genetic information, and could act as a
disincentive for settling disagreements.  Others have argued that the penalty clauses
are equivalent to those contained in other civil rights legislation, and that appropriate
penalties are necessary to deter discriminatory practices.
Title II:  Do the Bills Specify How Information May Flow Between a
Group Health Plan and an Employer?  S. 358 and H.R. 493 generally prohibit
employers from requesting or requiring genetic information about their employees.
This is more restrictive than what HIPAA currently permits.  HIPAA allows group
health plans to disclose health information — including genetic information — to plan
sponsors (employers) if certain conditions are met.  The conditions are generally
designed to allow sponsors to use the information to perform functions on behalf of
the group health plan (i.e., administer the plan and develop of new insurance
contracts), but not for employment-related actions (i.e., hiring and promotion
decisions).  Opponents of the legislation argue that such restrictions will create
confusion regarding which types of health information insurers can release to
employers, particularly if genetic information, which would have to be separated from
other health information and be withheld from employers, is not clearly defined.
Supporters of the legislation indicate that the bills would not change the foundation
of protections established by HIPAA and the privacy rule.  Instead, the net affect
would be to build upon that foundation, to clarify the role of genetic information in
the context of other health information, and to establish specific protections for
genetic information for entities that are not described by HIPAA (e.g, plan sponsors).
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Title II:  Would the Bills Create an Incentive for Suing Employers?
The bills would permit individuals to sue without first filing a complaint with the
EEOC.  Some have argued that this, coupled with the absence of a cap on
compensatory and punitive damages, would encourage frivolous litigation.56  Others
argue that, as with Title I, penalties are consistent with remedies under existing civil
rights legislation (e.g., ADA), and argue that they are necessary to assure compliance
with the provisions.
Title II:  Do the Bills Strike the Right Balance Between Public and
Individual Risk? S. 358 and H.R. 493 would not permit an employer to make an
employment decision based on predictive genetic information, even when there may
be some resulting risk to public health.  OSHA currently has guidelines for monitoring
for genetic changes associated with exposure in the workplace and susceptibility to
exposure (29 C.F.R. Part 1910).  Some argue that the bills should permit employers
to make decisions based on predictive genetic information in situations where the
public might be harmed (such as an employee carrying a gene predisposing him or her
to epilepsy when the employee is a bus driver).  Others stated that it was unfair to
deny healthy people opportunities when only a possibility of becoming ill existed.
Even if it could be known that a person would definitely become ill (as in the case
with those that have a gene for Huntington’s Disease), the precise time that the illness
would prevent the employee from doing his or her job could not be known.
Furthermore, they argue that allowing the use of predictive genetic information in
these circumstances would create bias against those people who happened to be
predisposed to a disease for which a test existed.  If two people were genetically
destined to become incapacitated at the same time, but by different diseases, and if
there happened to be a predictive test developed for only one of the diseases, the
person with a predisposition for that disease may be subject to adverse consequences
from the availability of the information, while the other person would not. 
Title II:  Should the Bills have a Sunset Clause?  S. 358 and H.R. 493
do not have a sunset clause. Some opponents argue that any genetic nondiscrimination
legislation should have an expiration date to enable public policy to keep pace with
scientific advances and allow Congress to decide how effectively the law has worked.
This type of sunset clause is unusual in civil rights legislation; there is only one
example of civil rights legislation that has an expiratory term.57  Supporters of
nondiscrimination legislation point out that Congress always reserves the right to
evaluate the effectiveness of laws and make modifications as deemed necessary.
Further, they do not believe that discrimination issues will go away in the near term.
For example, a sunset provision may not protect a person who agreed to be tested
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when the laws were in effect, but whose genetic information would then be in his or
her record after the laws expired.
Title II:  Should the Bills Require Separate Medical Files?  S. 358 and
H.R. 493 require employers to keep employees’ genetic information in separate
medical files.  The House Committee on Education and Labor adopted an amendment
to H.R. 493 on February 14, 2007, specifying that genetic information protected by the
act could be maintained with and treated as a confidential medical record under ADA
§102(d)(3)(B).  S. 358 contains no parallel provision.  
No federal or state law has a separate file requirement for group health plans
acting to provide medical services, even though some studies show some physicians
and genetics professionals are already keeping separate files in the absence of
protecting legislation.58  In fact, Executive Order 13145 already requires federal
agencies, acting as employers, to maintain genetic information as part of their
“confidential medical records which must be kept apart from personnel files.” Some
have argued that requiring maintenance of genetic information in separate files
increases potential for medical error.  Others point out that, because the language
states that the requirement applies only to employers, the risk of medical error would
only increase if Title II could be construed to include group health plans administering
employer-sponsored benefits, which is contrary to precedent. 
Title II:  Should the Bills Create a Safe Harbor? S. 358 and H.R. 493
would not preempt state laws.  The legislation would set a floor of basic federal
nondiscrimination regulations that would apply in all states, but would permit states
to keep or enact their own more comprehensive genetic nondisrcrimination legislation.
The bills would not provide a safe harbor, which would protect federally-compliant
employers from prosecution under state genetic nondiscrimination laws.  Because
states vary widely in their approaches to genetic nondiscrimination, opponents of
federal legislation proposed that any federal law should include a safe harbor
provision.  Supporters of the legislation argue that a federal floor is appropriate, and
that states should continue to be able to enact and test the effects of additional genetic
nondiscrimination provisions within their borders. 
Title I and Title II: How Do S. 358 and H.R. 493 
Protect Genetic Information?
An overarching question regarding S. 358 and H.R. 493 is how the bills would
protect genetic information.  The answer depends both on types of protections
(specifying what can be done with genetic information), and on the definition of
genetic information itself (specifying what is protected and what is not).  As discussed
in previous sections, the types of protections would primarily be restrictions on the
manner in which genetic information could be used in determining eligibility for
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health insurance, establishing premiums for health insurance, and in making decisions
regarding employment.  The definition of genetic information is discussed in detail
below.  
The bills define genetic information as — and therefore protect — knowledge
derived from a genetic test performed on individuals or their family members that
relates to the occurrence of a disease or disorder.  The protections would apply to
predictive genetic tests that provide information regarding a future  possible health
status of a currently non-affected person.  The bills’ precise definition of genetic
information, and thus protections that they would provide, hinge on factors discussed
below, including the definition of family medical history, differences between Title
I and Title II, and predictive versus manifested disease information combined with the
type of genetic test performed.
Family Medical History. S. 358 and H.R. 493 specify that genetic information
includes the fact that an individual or his/her family member has taken a genetic test.
The bills define family members to include distant relatives and adopted children
(which have no blood relationship and therefore would not be affected by genetic
information in the family).  Historically, genetic nondiscrimination act bills have
stressed the importance of family history.  The Senate report to accompany S. 1053
(108th) stated that “the committee realizes that family medical history could be used
as a surrogate for a genetic trait by a health plan or health insurance issuer ... it is
important to include family medical history in the definition of genetic information.”59
The report further clarified the concept of family medical history as being consistent
with the American Medical Association definition, and expected that the definition
would evolve over time.  Some debate has ensued over the  question of who should
be considered to be in one’s family.
The risk of sharing genetic traits or conditions is greatest in first and second-
degree blood relatives.60  The risk of sharing genes decreases as the blood relationship
becomes more distant.  For example, first degree relatives share  one-half of their
genetic material, second degree relatives share one-fourth, and third degree relatives
(first cousins), share one-eighth.  Fourth cousins, which are ninth degree relatives,
share only 1/512 of their genetic material.  At this level of relationship, only very rare
conditions appear more frequently in family members, and the risk of sharing many
common diseases is virtually the same as in the general population. 
Proponents of the legislation argue that the inclusion of individuals that have no
blood relation (i.e., adoptive children) is necessary to insure that the family remains
insurable as a unit; that adoptive children (or adoptive parents) are not penalized
because one or the other has a genetic trait that they themselves could not have.
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Opponents argued that inclusion of distant or non-blood related individuals further
extends the potential for litigation against insurers or employers.61
The House Education and Labor Committee Chairman’s version of H.R. 493 as
reported by the committee defined a  family member as someone related by blood
within four generations.  S. 358 contains no parallel provisions.   During the February
14, 2007, House Education and Labor Committee markup, a proposed amendment to
expand the definition of family member to include fetuses was defeated.  However,
the Chairman’s amended version of the bill contains provisions in Title I and Title II
specifying that the definition of genetic information (rather than family member)
would include that of a fetus.  S. 358 contains no similar provisions.  
While prenatal testing may be either diagnostic or predictive in nature, coverage
for a child does not usually begin until the moment of birth.62  In general, medical
insurance covers the named insured and dependents of the named insured.  Any
genetic information collected about a fetus while a woman is pregnant would likely
arise in the context of providing prenatal care to the insured woman.  Because the
fetus would not appear to be a separate insured individual, it seems likely that any
genetic information collected about the fetus would probably be attributed to the
woman as the named insured, and protected from discrimination to the extent that her
own medical information was protected. 
Differences Between Title I and Title II. The bills’ two titles define genetic
information differently and, therefore, apply different restrictions to employers and
insurers.  (See Table I).  Title I (health insurance provisions) specifically excludes
from its definition of genetic information — and therefore does not protect — medical
information that is not genetic information, including the analysis of proteins or
metabolites directly related to manifested disease, disorder, or pathological condition.
This exemption is not present in Title II (employment provisions), making the
definition of genetic information — and the scope of what is protected — broader for
employers than insurers.   In addition, the bills would permit health insurers to use or
disclose the individual’s current health status (as determined without a genetic test),
consistent with existing law.  This permission is not present in Title II, as employers
are already prohibited from using a person’s current health status in specific ways by
existing law.
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Table 1.  The Definition of Genetic Test and Genetic Information 
in Title I and Title II of S. 358 and H.R. 493
Title I
Health Insurance
Title II
Employment
Genetic test The term “genetic test” means the
analysis of human DNA, RNA,
chromosomes, proteins or
metabolites that detects
genotypes, mutations, or
chromosomal changes.
Same as Title I.
Limitations or
exemptions
“Genetic test” does not mean:
(i) an analysis of proteins or
metabolites that does not detect
genotypes, mutations, or
chromosomal changes; or
(ii) an analysis of proteins or
metabolites that is directly related
to a manifested disease, disorder,
or pathological condition that
could reasonably be detected by a
health care professional with
appropriate training and expertise
in the field of medicine involved.
“Genetic test” does not mean
an analysis of proteins or
metabolites that does not
detect genotypes, mutations, or
chromosomal changes.
Genetic
information
“Genetic information” means:
(i)  information about an
individual’s genetic tests;
(ii)  information about genetic
tests of family members of the
individual;
(ii)  information about the
occurrence of a disease or
disorder in family members.
Same as Title I.
Limitations or
exemptions
“Genetic information” does not
include information about the age
or sex of an individual.
Same as Title I.
Title I, Predictive vs.  Manifested Disease Information and Type of
Test. Title I of the bills focuses on protecting predictive information (i.e., information
about a future or potential health state in a currently symptom-free individual).  It does
so by exempting from the definition of genetic information analyses of proteins or
metabolites that are directly related to manifested diseases.  Insurers could thus use
this type of genetic information in accordance with current law governing insurance
and employment practices.   The definition of genetic test in the bills is more limited
than the medical or scientific definition of genetic test, which covers both predictive
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 For reference, the medical definition of genetic test includes the analysis of human
proteins and certain metabolites, which are predominantly used to detect heritable or
acquired genotypes (reflective of the individual’s DNA), mutations (actual changes in DNA
from the “normal” sequence), or phenotypes (a trait which is visible).  This definition covers
both diagnostic and predictive information with respect to current or future health status.
and diagnostic reasons for testing.63  Instances in which the distinction is blurred
between predictive information and that related to a manifested disease may cause
some confusion if the bills are enacted. 
Based upon the definition of genetic test in Title II, analyses of a person’s DNA
or RNA would be protected regardless of whether any related disease had manifested.
By contrast, as mentioned above, the definition of genetic test in Title I does not
include analyses that are both conducted on proteins or metabolites, and are directly
related to manifested diseases.  Thus, information derived from studying a protein or
metabolite would only be protected before symptoms appeared.  These provisions
create potentially unclear results when a single genetic test, which could be performed
on DNA or proteins, yields results that are both related to a manifested disease or
condition, and are predictive in nature.  The potential dilemma is illustrated by the
following example. 
    
If a person had cancer, a test of the tumor DNA or proteins may simultaneously
provide information about the tumor itself (a  manifested disease), and its likelihood
of recurrence (a predictive probability).  If surgery were performed to remove the
tumor and the patient went in to remission, the information obtained from the patients’
tumor could be considered both diagnostic for the previously manifested tumor and
predictive regarding a potential recurrence.  If the test had been performed on tumor
DNA, the information would be protected no matter whether it was considered to be
diagnostic or predictive.   However, if it had been performed on tumor proteins, if it
were considered diagnostic it would not be protected.  If it were considered predictive,
it would be.  (See Table 2). 
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Table 2.  Examples of Genetic Testing Scenarios 
and Protected Information Under S. 358 and H.R. 493
Scenario S. 358 and H.R. 493
Test of tumor proteins; information is
diagnostic, the tumor has not been removed.
Not Protected because “analysis is of protein ... is
directly related to a manifested disease.”
Test of tumor DNA; information is diagnostic,
the tumor has not been removed.
Protected, meets basic criteria for genetic test
(only protein or metabolite tests meet exclusion
for manifested disease).
Test of tumor proteins; tumor has been
removed;  information indicates the likelihood
of tumor recurrence.
Not Protected if the removed tumor is a
“manifested disease;” Protected if tumor removal
means that the disease is no longer manifested.
Test of tumor DNA; tumor has been removed;
information indicates the likelihood of tumor
recurrence.
Protected, meets basic criteria for genetic test, so
“manifested” is not an issue; limitation only
applies to tests of protein.
Test of tumor protein; information requested
for diagnostic purposes indicates resistence to
therapy.
Not Protected if information about possible drug
response is considered “directly related to
manifested disease;” Protected if not directly
related.
Test of tumor on patient’s DNA; information
requested for diagnostic purposes indicates
resistence to therapy.
Protected, meets basic criteria for genetic test, so
“directly related” is not an issue;  (only protein or
metabolite tests meet exclusion for manifested
disease).
This same lack of clarity may create issues in the case in which a person
undergoes a pharmacogenetic test, which is a genetic test to determine whether a
person is susceptible to adverse reactions to or beneficial results from a certain drug
or other treatment.  Information from pharmacogenomic tests reveals normal
variability in how different people’s bodies process different medications —
personalized medicine.  It is unclear whether this type of test would be protected under
current legislation.  Pharmacogenetic tests for individual susceptibilities to certain
drugs can be performed at any point in an individual’s life (i.e., when an individual
does not have a manifested disease). Thus, the scope of protections afforded to
pharmacogenomic test results might depend on whether the person already had a
disease for which the treatment was indicated.  Under the current definition it is
possible that, in the presence of manifested disease, information that a person would
not likely respond to a drug could potentially be used in a negative manner by health
insurers.  This may be of particular concern if only one treatment exists.
